Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Shionogi’s COVID Pill Effective for Non-Omicron Variants Too: President
October 14, 2022
- Fertility Drugs Face Supply Woes as Demand Spikes on Health Coverage
October 14, 2022
- Pfizer Seeks Japan Nod for BA.4/5-Tailored Vaccine for Ages 5-11
October 13, 2022
- Shionogi Delays Filing Plan for COVID-19 Vaccine to “By End of 2022”
October 13, 2022
- Shionogi to Test COVID Pill as Prophylaxis for Household Contacts from December
October 13, 2022
- Takeda to Discontinue Zejula Capsules, Urges Switch to Tablet Version
October 12, 2022
- Viatris Group to End Sale of 33 Products for Various Reasons
October 12, 2022
- Teikoku Seiyaku Pulls Plug on Kampo Business
October 12, 2022
- Kyushu Univ. Spinoff Aims to File NK-Like Cells in 2025, Eyes Combo with Checkpoint Drugs
October 11, 2022
- Japan Ethical Drug Sales Rise 6.3% in August: Crecon
October 11, 2022
- Moderna Probing Correlations between Spikevax Adverse Reactions and Immune Response: SVP
October 7, 2022
- Opdivo Top-Selling Drug in Japan for 9 Consecutive Months: Encise
October 7, 2022
- Santen’s Glaucoma Drug Accepted for Review in Europe
October 7, 2022
- Fujifilm to Launch Domestic Bio-CDMO Site in FY2026 to Bolster Vaccine Production
October 7, 2022
- Sumitomo to Incur 54 Billion Yen in Impairment Loss on Kynmobi
October 7, 2022
- Towa’s Win in Livalo Damage Suit Now Final and Binding
October 7, 2022
- Kyowa Kirin’s Venture Fund Invests in Cellarity
October 6, 2022
- Shionogi, UN Agency Tie Up for Generic Distribution of COVID Pill in Low-Middle-Income Nations
October 5, 2022
- Astellas/Pantherna Expand mRNA-Based Regenerative Medicine Collab to Add New Target Organ
October 5, 2022
- Moderna Files BA.4/5-Tailored COVID-19 Vaccine in Japan
October 5, 2022
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…